Page last updated: 2024-09-02

ecteinascidin 743 and Soft Tissue Neoplasms

ecteinascidin 743 has been researched along with Soft Tissue Neoplasms in 59 studies

Research

Studies (59)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (15.25)	29.6817
2010's	27 (45.76)	24.3611
2020's	23 (38.98)	2.80

Authors

Authors	Studies
Caldari, E; De Paolis, M; Fiore, M; Giannini, C; Pirini, MG; Sambri, A; Spinnato, P; Zucchini, R	1
Carrabotta, M; De Feo, A; Donati, DM; Durante, G; Giusti, V; Laginestra, MA; Landuzzi, L; Lollini, PL; Manara, MC; Mancarella, C; Palmerini, E; Parra, A; Pasello, M; Righi, A; Ruzzi, F; Scotlandi, K; Toracchio, L	1
Albert, S; Bessede, A; Blay, JY; Brahmi, M; Chakiba, C; Cousin, S; Croce, S; Floquet, A; Giraud, A; Guégan, JP; Italiano, A; Kind, M; Mathoulin-Pelissier, S; Perret, R; Pulido, M; Ray-Coquard, I; Toulmonde, M; Toulza, E	1
Bagué, S; Cerdà Serdà, P; López-Pousa, A; Moreno, ME; Orellana, R; Riba, M; Sebio, A; Terés, R	1
Coukos, G; Digklia, A; Homicsko, K	1
Grimison, P; King, D; Thomson, K; Zhou, DD	1
Casali, PG; Celant, S; Comandone, A; Di Segni, S; Napolitano, A; Olimpieri, PP; Russo, P; Sanfilippo, R; Vincenzi, B	1
Grignani, G; Le Cesne, A; Martín-Broto, J	2
Le Cesne, A	1
Aubry, S; Chaigneau, L; Charon Barra, C; Hervieu, A; Isambert, N; Jary, M; Kalbacher, E; Meynard, G; Nerich, V; Neumann, F	1
Aquilano, M; Becherini, C; Campanacci, DA; Francolini, G; Greto, D; Livi, L; Loi, M; Mangoni, M; Melica, ME; Salvatore, G; Salvestrini, V; Santini, C; Sottili, M; Talamonti, C; Valzano, M	1
Ae, K; Fukuda, N; Hayakawa, K; Hayashi, N; Matsumoto, S; Minami, Y; Nakano, K; Ohmoto, A; Oki, R; Ono, M; Saito, M; Sato, Y; Suto, H; Takahashi, S; Tanizawa, T; Tomomatsu, J; Udagawa, S; Urasaki, T; Wang, X; Yunokawa, M	1
Alvarez, R; Blay, JY; Casali, PG; Cruz Jurado, J; Dei Tos, AP; Fabbroni, C; Gronchi, A; Gutierrez, A; Hindi, N; Italiano, A; Lopez-Pousa, A; Martin-Broto, J; Morosi, C; Pérez Aguiar, JL; Ranchere-Vince, D; Rincón-Perez, I; Romagosa, C; Romero, J; Sanfilippo, R; Sangalli, C; Sunyach, MP	1
Meeus, P; Ray-Coquard, I; Turinetto, M	1
Assi, T; Cesne, AL	1
Assi, T; Bahleda, R; Faron, M; Hénon, C; Honoré, C; Le Cesne, A; Le Péchoux, C; Lévy, A; Ngo, C; Verret, B	1
Hayakawa, K; Iwata, S; Kobayashi, H; Oka, H; Tanaka, S; Ueda, T; Wakamatsu, T; Wasa, J; Yonemoto, T	1
Jones, RL; Martín-Broto, J; Reichardt, P; Stacchiotti, S	1
Arndt, K; Bornhäuser, M; Chemnitz, JM; Freitag, J; Grünwald, V; Hentschel, L; Hornemann, B; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Pelzer, U; Richter, S; Schilling, A; Schuler, MK; Schuler, U	1
Asanuma, K; Hagi, T; Nakamura, T; Sudo, A	1
Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M	1
Blažičević, K; Golčić, M; Herceg, D; Ladenhauser, T; Majnarić, T; Simetić, L	1
Aglietta, M; Aliberti, S; Bardelli, A; Bartolini, A; Bertulli, R; Boccone, P; Chiabotto, G; D'Ambrosio, L; D'Incalci, M; Dei Tos, AP; Ferrari, S; Grignani, G; Marchesi, E; Miano, S; Novara, L; Palmerini, E; Piana, R; Picci, P; Pignochino, Y; Pisacane, A; Sangiolo, D; Stacchiotti, S; Tolomeo, F; Zucchetti, M	1
Esser, M; Fritz, J; Horger, M; Kloth, C; Kopp, HG; Reinert, CP; Thaiss, WM	1
Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N	1
Baldi, GG; Gronchi, A; Suarez-Kelly, LP	1
Iwasaki, J; Komori, T; Matsuo, K; Nagase, H; Nakagawa, F; Uchida, J; Uto, Y	1
Constantinidou, A; Jones, RL; Loggers, E; Pollack, S; Rodler, E	1
Brodowicz, T; Eisterer, W; Köstler, WJ; Kühr, T; Lamm, W; Lindorfer, A; Ploner, F; Schur, S; Szkandera, J; Tinchon, C	1
Elias, A; Gajdos, C; Lopez, JP	1
Bertucci, F; Chaire, V; Italiano, A; Laroche-Clary, A; Le Morvan, V; Neuville, A; Pourquier, P; Salas, S; Sanfilippo, R	1
Bay, JO; Bertucci, F; Blay, JY; Chevreau, C; Clisant, S; Delcambre, C; Domont, J; Isambert, N; Italiano, A; Le Cesne, A; Mir, O; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Ryckewaert, T; Saada-Bouzid, E; Tresch-Bruneel, E; Valentin, T	1
Cable, MG; Randall, RL	1
Alexandre, J; Bertucci, F; Bompas, E; Chevreau, C; Collard, O; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Guillemet, C; Isambert, N; Lacas, B; Lavau-Denes, S; Le Cesne, A; Pautier, P; Penel, N; Piperno-Neumann, S; Selle, F; Soulié, P; Thyss, A; Toulmonde, M	1
Reichardt, P	1
Le Cesne, A; Reichardt, P	1
Grignani, G; Martín-Broto, J; Reichardt, P; Schuler, M	1
Badalamenti, G; Cerbone, L; De Lisi, D; Frezza, AM; Maltese, G; Santini, D; Silletta, M; Spalato Ceruso, M; Stumbo, L; Tonini, G; Vincenzi, B	1
Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V	1
Casali, PG; Collini, P; D'Incalci, M; Dileo, P; Gronchi, A; Grosso, F; Jimeno, J; Morosi, C; Pilotti, S; Piovesan, C; Sanfilippo, R; Tercero, JC; Virdis, E	1
Alfaro, V; Blay, JY; Bonvalot, S; Cioffi, A; Domont, J; Le Cesne, A; Lebedinsky, C; Ray-Coquard, I; Santabarbara, P; Terrier, P	1
Cohen, AF; Dubois, EA	1
Dimitrakopoulou-Strauss, A; Egerer, G; Ho, AD; Kasper, B; Schmitt, T; Wuchter, P	1
Croué, A; Pavageau, AH; Reguerre, Y; Rialland, X; Rousselet, MC	1
Bui-Nguyen, B; Italiano, A; Toulmonde, M	1
Casali, PG; D'Incalci, M; Sanfilippo, R	1
Papaioannou, D; Rafia, R; Simpson, EL; Stevenson, MD	1
Balañá, C; Bellmunt, J; Buesa, JM; Casado, A; Ciruelos, E; Cortes-Funes, H; del Muro, JG; Izquierdo, MA; López-Pousa, A; Nieto, A; Paz-Ares, L; Poveda, A; Provencio, M; Rivera-Herrero, F; Tanović, A	1
Contreras Ibáñez, JA; Díaz Gómez, L; Navas García, N	1
Movva, S; Verschraegen, C	1
Adamson, PC; Baker, KS; Baruchel, S; Blaney, SM; Krailo, M; Lee-Scott, M; Pappo, A; Villaluna, D; Wu, B	1
Shi, YQ	1
Alexandre, J; Blay, JY; Brain, E; Cvitkovic, E; Jimeno, J; Kahatt, C; Martin, C; Misset, JL; Riofrio, M; Salhi, Y; Taamma, A; Yovine, A	1
Canniff, J; Demetri, GD; Garcia-Carbonero, R; Gomez, J; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Matulonis, U; Merriam, P; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG	1
Verweij, J	1
Demetri, GD; Garcia-Carbonero, R; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG; Waxman, A	1

Reviews

17 review(s) available for ecteinascidin 743 and Soft Tissue Neoplasms

Article	Year
The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives. Current treatment options in oncology, 2021, 10-23, Volume: 22, Issue:12 Topics: Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Epigenomics; Gene Expression Regulation, Neoplastic; Genomics; Humans; Ifosfamide; Indazoles; Molecular Targeted Therapy; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma, Synovial; Soft Tissue Neoplasms; Sulfonamides; Surgical Procedures, Operative; Trabectedin	2021
A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma. Future oncology (London, England), 2022, Volume: 18, Issue:30s Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Quality of Life; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2022
Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes. Future oncology (London, England), 2022, Volume: 18, Issue:30s Topics: Aged; Antineoplastic Agents, Alkylating; Dioxoles; Humans; Quality of Life; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2022
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients. Current opinion in oncology, 2023, 07-01, Volume: 35, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Leiomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2023
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review. Current treatment options in oncology, 2023, Volume: 24, Issue:11 Topics: Doxorubicin; Humans; Liposarcoma; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2023
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype. Expert review of anticancer therapy, 2020, Volume: 20, Issue:sup1 Topics: Animals; Antineoplastic Agents, Alkylating; Humans; International Cooperation; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2020
Therapeutic Targets for Bone and Soft-Tissue Sarcomas. International journal of molecular sciences, 2019, Jan-04, Volume: 20, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin	2019
Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:12 Topics: Adult; Anthracyclines; Antineoplastic Agents; Drug Discovery; Drugs, Investigational; Furans; Humans; Ketones; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2019
The evolution of systemic therapy in sarcoma. Expert review of anticancer therapy, 2013, Volume: 13, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chordoma; Deoxycytidine; Dermatofibrosarcoma; Dioxoles; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Hemangiosarcoma; Humans; Osteosarcoma; Proteasome Inhibitors; Receptor, IGF Type 1; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin	2013
Trabectedin: novel insights in the treatment of advanced sarcoma. Current oncology reports, 2014, Volume: 16, Issue:6 Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Drug Therapy, Combination; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2014
Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dioxoles; Disease Progression; Drug Administration Schedule; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Palliative Care; Patient Selection; Randomized Controlled Trials as Topic; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic	2015
Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:6 Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Humans; Pharmacogenetics; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2009
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines]. Bulletin du cancer, 2010, Volume: 97, Issue:6 Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin	2010
Trabectedin therapy for sarcomas. Current opinion in oncology, 2010, Volume: 22, Issue:4 Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome	2010
Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1 Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dioxoles; Disease Progression; Health Care Costs; Humans; Kaplan-Meier Estimate; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; United Kingdom	2010
Systemic management strategies for metastatic soft tissue sarcoma. Drugs, 2011, Nov-12, Volume: 71, Issue:16 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lysine; Paclitaxel; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2011
[Development of multidisciplinary treatment for soft tissue sarcoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2012

Trials

9 trial(s) available for ecteinascidin 743 and Soft Tissue Neoplasms

Article	Year
Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). BMJ open, 2020, 08-27, Volume: 10, Issue:8 Topics: Humans; Palliative Care; Quality of Life; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2020
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. The Lancet. Oncology, 2018, Volume: 19, Issue:10 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Italy; Male; Middle Aged; Osteosarcoma; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Sarcoma; Soft Tissue Neoplasms; Time Factors; Trabectedin	2018
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Substitution; Female; France; Humans; Infusions, Intravenous; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Young Adult	2015
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms	2015
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dioxoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Sarcoma; Soft Tissue Neoplasms; Spain; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult	2012
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:4 Topics: Adolescent; Adult; Algorithms; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Male; Medical Oncology; Pediatrics; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Societies, Medical; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Young Adult	2012
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-01, Volume: 22, Issue:5 Topics: Adult; Aged; Biological Availability; Biopsy, Needle; Dioxoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasm Staging; Probability; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome	2004
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-15, Volume: 22, Issue:8 Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Tetrahydroisoquinolines; Trabectedin	2004
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome	2005

Other Studies

33 other study(ies) available for ecteinascidin 743 and Soft Tissue Neoplasms

Article	Year
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. Cancer research, 2022, 02-15, Volume: 82, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Kaplan-Meier Estimate; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Sarcoma; Signal Transduction; Soft Tissue Neoplasms; Trabectedin; Tumor Burden; Xenograft Model Antitumor Assays	2022
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 05-02, Volume: 28, Issue:9 Topics: Antibodies, Monoclonal; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2022
Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas. Advances in therapy, 2022, Volume: 39, Issue:4 Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Humans; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2022
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 05-02, Volume: 28, Issue:9 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2022
Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results. Asia-Pacific journal of clinical oncology, 2022, Volume: 18, Issue:5 Topics: Antineoplastic Agents, Alkylating; Australia; Clinical Trials as Topic; Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2022
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry. International journal of cancer, 2023, 02-15, Volume: 152, Issue:4 Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Male; Registries; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2023
The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data. Future oncology (London, England), 2022, Volume: 18, Issue:30s Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2022
Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis. Oncology, 2022, Volume: 100, Issue:12 Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2022
Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells. International journal of molecular sciences, 2022, Nov-18, Volume: 23, Issue:22 Topics: Antineoplastic Agents, Alkylating; Fibrosarcoma; Humans; Leiomyosarcoma; Liposarcoma; Radiation-Sensitizing Agents; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Tumor Microenvironment	2022
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study. PloS one, 2023, Volume: 18, Issue:3 Topics: Adult; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2023
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial. JAMA oncology, 2023, 05-01, Volume: 9, Issue:5 Topics: Adult; Antineoplastic Agents, Alkylating; Female; Humans; Liposarcoma, Myxoid; Male; Neoplasm Recurrence, Local; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2023
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes? Future oncology (London, England), 2023, Volume: 19, Issue:28 Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2023
Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study. Cancer, 2020, 03-15, Volume: 126, Issue:6 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Body Height; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Neutropenia; Product Surveillance, Postmarketing; Progression-Free Survival; Retrospective Studies; Rhabdomyolysis; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Young Adult	2020
Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan. Drug design, development and therapy, 2020, Volume: 14 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Female; Furans; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Ketones; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Survival Analysis; Trabectedin; Treatment Outcome	2020
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer medicine, 2021, Volume: 10, Issue:11 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascular Diseases; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Doxorubicin; Female; Heart; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Product Surveillance, Postmarketing; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Stroke Volume; Trabectedin; Ventricular Function, Left; Young Adult	2021
Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin. Anti-cancer drugs, 2021, 11-01, Volume: 32, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Young Adult	2021
CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin. European journal of radiology, 2018, Volume: 107 Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Male; Middle Aged; Peritoneal Neoplasms; Retrospective Studies; Sarcoma; Sensitivity and Specificity; Soft Tissue Neoplasms; Tomography, X-Ray Computed; Trabectedin	2018
Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines. Anticancer research, 2019, Volume: 39, Issue:7 Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins; Sarcoma; Soft Tissue Neoplasms; Trabectedin	2019
The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS). Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Austria; Dioxoles; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult	2013
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. British journal of cancer, 2015, Feb-17, Volume: 112, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; BRCA1 Protein; Clinical Trials, Phase II as Topic; Compassionate Use Trials; Dioxoles; Drug Resistance, Neoplasm; Female; Haplotypes; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult	2015
Trabectedin tactics: from sea squirts to sarcomas. The Lancet. Oncology, 2015, Volume: 16, Issue:3 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Female; Humans; Male; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2015
Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword. Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2015
Trabectedin clinical cases: use according to indication in diverse clinical scenarios. Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms	2015
Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. Scientific reports, 2015, Aug-03, Volume: 5 Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2015
In brief: Two Drugs for soft-tissue sarcoma. The Medical letter on drugs and therapeutics, 2016, May-09, Volume: 58, Issue:1494 Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Furans; Humans; Ketones; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Tubulin Modulators	2016
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. European journal of cancer (Oxford, England : 1990), 2017, Volume: 76 Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays	2017
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposarcoma, Myxoid; Male; Middle Aged; Retrospective Studies; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Trabectedin	2009
Trabectedin. British journal of clinical pharmacology, 2009, Volume: 68, Issue:3 Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2009
Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects. Prescrire international, 2009, Volume: 18, Issue:102 Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Drug Approval; Europe; Humans; Orphan Drug Production; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2009
The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin. Marine drugs, 2009, Jul-17, Volume: 7, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Positron-Emission Tomography; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome	2009
[A rare tumour with a distinctive histological appearance]. Annales de pathologie, 2010, Volume: 30, Issue:2 Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteriovenous Malformations; Bevacizumab; Biomarkers, Tumor; Combined Modality Therapy; Dactinomycin; Desmin; Diagnosis, Differential; Dioxoles; Doxorubicin; Humans; Ifosfamide; Leg; Lung Neoplasms; Male; Neoplasm Proteins; Prognosis; S100 Proteins; Sarcoma, Alveolar Soft Part; Soft Tissue Neoplasms; Staining and Labeling; Tetrahydroisoquinolines; Trabectedin; Vincristine	2010
Mestastatic gastric cancer from malignant fibrous histiocytoma. Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dioxoles; Docetaxel; Epirubicin; Fatal Outcome; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Lung Neoplasms; Male; Soft Tissue Neoplasms; Spinal Neoplasms; Stomach Neoplasms; Taxoids; Tetrahydroisoquinolines; Thigh; Thoracic Vertebrae; Trabectedin	2011
Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Humans; Isoquinolines; Research Design; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin	2005